Rapid Resolution Lifts Hold on Tenaya’s Gene Therapy Trial
FDA has lifted the clinical hold on Tenaya’s MyPEAK-1 Phase 1b/2a trial of TN-201 in MYBPC3-associated hypertrophic cardiomyopathy, with...
eClinical Tech News
Akari Therapeutics Starts GMP Manufacturing for Phase 1 Trial
Akari Therapeutics has initiated GMP manufacturing for AKTX-101, its Trop2-targeted antibody-drug conjugate built around a proprietary spliceosome-modulating payload (PH1)....
Quantum Biopharma Completes Dosing in Lucid-MS Toxicity Study
Quantum BioPharma has completed oral dosing in 180-day chronic toxicity and toxicokinetic studies for Lucid-21-302 (Lucid-MS), its preclinical remyelination...
Immuneering to Post Survival Data in Pancreatic Cancer Trial
No new efficacy data were released, but Immuneering set January 7, 2026, for a 12‑month overall survival update from...
INVIVYD Launches Phase 3 Trial for COVID Antibody VYD2311
In earlier Phase 1/2 testing, intramuscular VYD2311 given at four times the planned Phase 3 dose was well tolerated,...
Promising Lupus Drug LBL-047 Enters Phase 1 Trial
No efficacy data yet. Leads Biolabs and Dianthus have dosed the first subject in a double-blind, randomized, placebo-controlled Phase...
Biosplice Doses First Patient in Ovarian Cancer Trial
Biosplice Therapeutics has initiated dosing in an investigator-initiated Phase 1 study testing cirtuvivint, a pan-CLK/DYRK inhibitor, in combination with...
Neonc Technologies Announces Updated Clinical Trial Results
In an expanded 25-patient Phase 1/2a plus compassionate-use cohort of recurrent WHO Grade III/IV IDH1-mutant astrocytoma, intranasal NEO100 produced...
Elraglusib Shows Promising Results in Phase II Cancer Study
Median overall survival reached 18.6 months across 32 patients with metastatic salivary gland cancers treated with elraglusib plus carboplatin...
Precision Medicine Update: China Study & FDA Resubmissions
Telix reported a 94.8% overall patient-level PPV (95% CI: 85.9%–98.2%) in its 140-patient Phase 3 registration study of TLX591-CDx...